Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Treasury Shares (2022 - 2025)

Gain Therapeutics (GANX) has 4 years of Treasury Shares data on record, last reported at $24568.0 in Q3 2025.

  • For Q3 2025, Treasury Shares fell 76.08% year-over-year to $24568.0; the TTM value through Sep 2025 reached $24568.0, down 76.08%, while the annual FY2024 figure was $102702.0, 79.2% down from the prior year.
  • Treasury Shares reached $24568.0 in Q3 2025 per GANX's latest filing, down from $28833.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $598150.0 in Q2 2023 and bottomed at $24568.0 in Q3 2025.
  • Average Treasury Shares over 4 years is $253685.8, with a median of $212089.5 recorded in 2023.
  • Peak YoY movement for Treasury Shares: soared 62.94% in 2023, then tumbled 79.71% in 2024.
  • A 4-year view of Treasury Shares shows it stood at $303050.0 in 2022, then soared by 62.94% to $493799.0 in 2023, then tumbled by 79.2% to $102702.0 in 2024, then plummeted by 76.08% to $24568.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $24568.0 in Q3 2025, $28833.0 in Q2 2025, and $91149.0 in Q1 2025.